Company Profile
Public information reviewed
Sana Biotechnology, Inc.
Canonical company identity and public leadership record.
USNASDAQ: SANA
Follow
More
- Public sources
- 1 reviewed
- Published leadership records
- 16
- Last reviewed
- Sep 16, 2026
Agent View
Machine representations
Inspect the same governed public record as Markdown, structured data, or a retrieval endpoint.
Markdown
https://registry.alpha.ac/companies/sana-biotechnology-inc.mdSana Biotechnology, Inc.
Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero.
Record
| Field | Value |
|---|---|
| Representation | alpha-profile-markdown-v3 |
| Protocol | Alpha Governance Facts Protocol 0.1 |
| Schema | alpha.governance.entity.public.v1 |
| Record version | public-1 |
| Canonical entity | alpha:company:efda9614-03aa-400b-958e-bfae693103b2 |
| Entity type | Company |
| Canonical URL | https://registry.alpha.ac/companies/sana-biotechnology-inc |
| Publication | PUBLISHED |
| Verification | source_reported |
| Verification schema | alpha-verification-states-v1 |
| Ownership | unclaimed |
| Published claims | 19 |
| Claims under review | 1 |
| Evidence records | 4 |
| Conflicts | 0 |
| Conflicts in internal review | 0 |
| Observed | 2026-09-16T04:46:04.746414+00:00 |
| Last reviewed | 2026-09-16T04:46:04.746414+00:00 |
Identity
- Legal name: Sana Biotechnology, Inc.
- Display name: Sana Biotechnology, Inc.
Leadership
- Hans E. Bishop: Chairman of the Board. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:2.
- Alise S. Reicin: Director. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:3.
- Alise S. Reicin, M.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:2.
- Joshua H. Bilenker: Director. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:3.
- Joshua H. Bilenker, M.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:2.
- Mary Agnes Wilderotterº: Director. Valid from: 2026-04-24. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:3.
- Michelle Seitz, CFA: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:2.
- Patrick Y. Yang: Director. Valid from: 2018-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:3.
- Patrick Y. Yang, Ph.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:2.
- Richard Mulligan: Director. Valid from: 2018-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:3.
- Richard Mulligan, Ph.D.: Vice-Chairman of the Board. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:2.
- Robert L. Rosiello: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:2.
- Robert Nelsen: Director. Valid from: 2018-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:3.
- Steven D. Harr, M.D.: President, Chief Executive Officer and Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:2.
- Bernard J. Cassidy: Chief Financial Officer. Valid from: 2026-04-24. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:4.
- Steven D. Harr, M.D.: President and Chief Executive Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:2.
Roles
- PUBLISHED
Governance
- NOT_ASSERTED
Board committees
- PUBLISHED
Financials
- NOT_ASSERTED
Workforce
- NOT_ASSERTED
Market and index context
- PUBLISHED
Legal Name
- Sana Biotechnology, Inc.. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:1.
Headquarters
- US. Publication: UNDER_REVIEW. Verification: source_reported. Assertion: source_reported. Evidence: unlinked, under review.
Entity Status
- Public listing published. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:1.
Published Fact
- US. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:1.
Coverage states
| Field | Value |
|---|---|
| Identity | PUBLISHED |
| Business | PUBLISHED |
| Leadership | PUBLISHED |
| Board and committees | PUBLISHED |
| Governance | NOT_ASSERTED |
| Financials | NOT_ASSERTED |
| Workforce | NOT_ASSERTED |
| Ownership | NOT_ASSERTED |
| Ratings | NOT_PUBLISHED |
| Market and index context | PUBLISHED |
Public sources
- alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:1: Alpha canonical company public projection.
- alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:2: SEC DEF 14A 0001193125-26-174883.
- alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:3: DEF 14A d42230ddef14a.htm.
- alpha:evidence:company:efda9614-03aa-400b-958e-bfae693103b2:4: SANA DEF 14A executive officers.
Rights
| Field | Value |
|---|---|
| public_retrieval | allowed |
| agent_retrieval | allowed |
| redistribution | not_granted |
| model_training | not_granted |
| commercial_use | not_specified |
| relationship_pathfinding | not_granted |
| direct_contact | not_granted |
Limitations
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.
Alternate representations
- Canonical profile
- Public Markdown
- Public JSON
- JSON-LD
- MCP resource:
alpha://companies/sana-biotechnology-incat https://mcp.alpha.ac/mcp